Till innehåll

Press releases

The latest news and updates from Oncopeptides

Filter
Category
News / Categories
Type
Press releases / Type
Year
Regulatory
November 9, 2026
European Commission approves label expansion of Pepaxti to third-line treatment
Regulatory
November 5, 2026
Oncopeptides publishes Q3 report 2026
Investor
Regulatory
November 4, 2026
New European real-world evidence supporting Pepaxti in heavily pretreated multiple myeloma to be presented at ASH 2026
CompanyScience
October 29, 2026
Invitation to presentation of the Q3 report 2026
Investor
October 9, 2026
Invitation to Oncopeptides’ investor webcast following positive glioblastoma data
CompanyInvestor
October 9, 2026
Oncopeptides confirms blood-brain-barrier penetration based on data from first patients in glioblastoma Window-of-Opportunity study
Company
Regulatory
September 22, 2026
Preclinical and translational glioblastoma data to be presented at EANO 2026, Oncopeptides nominated for prestigious EANO 2026 Poster award
Science
September 21, 2026
Oncopeptides to highlight clinical progress and present new data at the IMS Annual Meeting
Science
September 17, 2026
CHMP issues positive opinion of label expansion of Pepaxti to third-line treatment
Regulatory
Select language or region
Region

Learn more about the company Oncopeptides and the work we do to redefine cancer care

Learn more about the company Oncopeptides and the work we do to redefine cancer care

Learn more about the company Oncopeptides and the work we do to redefine cancer care

Learn more about the company Oncopeptides and the work we do to redefine cancer care